Advisory for Digital Health Founders, Health Systems, and Investors
I've spent almost 20 years building healthcare companies, from early-stage startups to scaled platforms. I advise founders, health system executives, and investors navigating AI diagnostics, lung cancer screening, FQHC partnerships, and the reimbursement landscape.What I Advise On
I focus on the problems that stall healthcare companies: distribution, reimbursement, and clinical trust. Not just technology.AI Diagnostics Strategy
Embedding AI into clinical workflows, FDA and regulatory pathways, building radiologist trust, and designing products physicians actually adopt.
Lung Cancer Screening
LDCT screening program design, CMS reimbursement (G0296, G0297), patient identification and outreach, and shared decision-making requirements.
FQHC Partnerships
Selling to Federally Qualified Health Centers, understanding their funding model, navigating UDS reporting, and building sustainable partnerships.
Healthtech Go-to-Market
Distribution strategy for health systems and payers, pricing and reimbursement models, pilot design, and moving from POC to contract.
Fundraising and Investor Strategy
Pitch narrative for healthtech, investor targeting (healthcare-specific vs. generalist), data rooms, and what diligence looks like in this space.
Healthtech Due Diligence
For investors evaluating AI diagnostics, digital health, or cancer screening companies. I help assess clinical validity, reimbursement risk, and market positioning.
Who This Is For
- Digital health founders building AI products for clinical settings
- Health system executives evaluating AI screening or diagnostic programs
- Investors conducting diligence on healthtech, AI diagnostics, or cancer screening deals
- Founders navigating FQHC sales, CMS reimbursement, or payer contracting
- Early-stage teams deciding between clinical vs. operational AI use cases
- Companies preparing for accelerator applications or fundraising